TP53 and ovarian carcinoma: Here, we examined validity and specificity of p53-MCL analyzing 15 LCLs from familial breast and ovarian cancer cases and fresh PBMCs from a total of 496 cases including BRCA1/2-positive and -negative familial breast and ovarian cancer and different sporadic cancers.